Shibing Tang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shibing Tang has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Bing Yang
Zhejiang University
4 shared publications Gengwu Li
Guangdong Provincial Key Laboratory of Biocomputing, Institute of Drug Discovery, Guangzhou Institutes of Biomedicine and Health
3 shared publicationsJing Tian
State Key Laboratory of Respiratory Disease, Institute of Drug Discovery, Guangzhou, Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China
3 shared publicationsYinuo Lin
State Key Laboratory of Respiratory Disease, Center for Chemical Biology and Drug Discovery, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China
3 shared publications- Dan Liu
Zhejiang Key Laboratory of Soil Remediation and Quality Improvement, College of Environment and Resources, College of Carbon Neutrality, Zhejiang A&F University, Hangzhou 311300, China
2 shared publications Jianguang Liu
Guangdong Provincial Key Laboratory of Biocomputing, Institute of Drug Discovery, Guangzhou Institutes of Biomedicine and Health
2 shared publications
Latest Publications
- 5 February 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (4) , 4829-4854
Discovery and Optimization of 4-Aminopteridin-7(8 H )-one Derivatives as Potent and Selective mTOR Inhibitors with Favorable Pharmacodynamic and Safety Characteristics
The mechanistic target of rapamycin (mTOR) is a central regulator of cell growth and a promising cancer therapeutic target. Using structure-guided design, we developed novel 4-aminopteridin-7(8H)-one derivatives as ATP-competitive mTOR inhibitors. The lead compound T133 (51) demonstrated exceptional mTOR inhibition (Ki = 0.17 nM) with high selectivity, effectively suppressing phosphorylation of downstream effectors, such as AKT, S6K1, and 4EBP1. In HGC-27 gastric cancer cells, T133 potently inhibited proliferation and migration while inducing apoptosis, cell cycle arrest, and autophagy. This efficacy extended to NCI-H1299 lung cancer and T-47D breast cancer cells. In the HGC-27 xenograft mouse model, oral administration of T133 exhibited dose-dependent efficacy comparable to clinical-stage inhibitor PF-04691502, while exhibiting significantly reduced hepatotoxicity, nephrotoxicity, and pulmonary toxicity. Moreover, assessments of T133 on cytochrome P450, hERG, and AMES indicate a favorable safety profile. These findings suggest T133 is a promising mTOR inhibitor, warranting further investigation for cancer therapy.
- 5 February 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (4) , 4829-4854
Discovery and Optimization of 4-Aminopteridin-7(8 H )-one Derivatives as Potent and Selective mTOR Inhibitors with Favorable Pharmacodynamic and Safety Characteristics
The mechanistic target of rapamycin (mTOR) is a central regulator of cell growth and a promising cancer therapeutic target. Using structure-guided design, we developed novel 4-aminopteridin-7(8H)-one derivatives as ATP-competitive mTOR inhibitors. The lead compound T133 (51) demonstrated exceptional mTOR inhibition (Ki = 0.17 nM) with high selectivity, effectively suppressing phosphorylation of downstream effectors, such as AKT, S6K1, and 4EBP1. In HGC-27 gastric cancer cells, T133 potently inhibited proliferation and migration while inducing apoptosis, cell cycle arrest, and autophagy. This efficacy extended to NCI-H1299 lung cancer and T-47D breast cancer cells. In the HGC-27 xenograft mouse model, oral administration of T133 exhibited dose-dependent efficacy comparable to clinical-stage inhibitor PF-04691502, while exhibiting significantly reduced hepatotoxicity, nephrotoxicity, and pulmonary toxicity. Moreover, assessments of T133 on cytochrome P450, hERG, and AMES indicate a favorable safety profile. These findings suggest T133 is a promising mTOR inhibitor, warranting further investigation for cancer therapy.
- Open Access
- 15 July 2025
- Published by Springer Nature in Genome Biology
- Vol. 26 (1) , 1-20
Enrichable cross-linkers for mapping direct protein interactions
It is crucial to investigate protein functions in specific subcellular environments. Cross-linking mass spectrometry is a powerful tool to map the direct interactome of proteins by identifying inter-protein cross-links. However, it is challenging to identify inter-protein cross-linked peptides due to their low abundance. We chemically synthesize the cross-linkers ePDES1 and ePDES2 with an alkyne group and a compound with azide linked to a phosphate group to enrich for cross-linked peptides. Based on the high-quality cross-linking spectra of ePDES1 and ePDES2, our methods achieve the identification of hundreds of directly interacting proteins or substrates of thioredoxins in the nucleus and mitochondria.
- 15 July 2025
- Published by Springer Nature in Genome Biology
- Vol. 26 (1) , 1-20
Open AccessEnrichable cross-linkers for mapping direct protein interactions
It is crucial to investigate protein functions in specific subcellular environments. Cross-linking mass spectrometry is a powerful tool to map the direct interactome of proteins by identifying inter-protein cross-links. However, it is challenging to identify inter-protein cross-linked peptides due to their low abundance. We chemically synthesize the cross-linkers ePDES1 and ePDES2 with an alkyne group and a compound with azide linked to a phosphate group to enrich for cross-linked peptides. Based on the high-quality cross-linking spectra of ePDES1 and ePDES2, our methods achieve the identification of hundreds of directly interacting proteins or substrates of thioredoxins in the nucleus and mitochondria.
- 22 March 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 290, 117560
Recent advances in medicinal chemistry strategies for the development of METTL3 inhibitors
- 22 March 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 290, 117560
Recent advances in medicinal chemistry strategies for the development of METTL3 inhibitors
- 18 June 2024
- Published by Royal Society of Chemistry (RSC) in New Journal of Chemistry
- Vol. 48 (27) , 12081-12085
Efficient synthesis of 1-azakenpaullone, a selective inhibitor of glycogen synthase kinase-3β for cellular regeneration
The selective GSK-3β inhibitor 1-azakenpaullone has broad applications in cellular regeneration and regenerative medicine. A two-step protocol featuring an indium-trichloride-mediated intramolecular cyclization to 1-azakenpaullone is disclosed.
- 18 June 2024
- Published by Royal Society of Chemistry (RSC) in New Journal of Chemistry
- Vol. 48 (27) , 12081-12085
Efficient synthesis of 1-azakenpaullone, a selective inhibitor of glycogen synthase kinase-3β for cellular regeneration
The selective GSK-3β inhibitor 1-azakenpaullone has broad applications in cellular regeneration and regenerative medicine. A two-step protocol featuring an indium-trichloride-mediated intramolecular cyclization to 1-azakenpaullone is disclosed.
- Open Access
- 18 June 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-13
Characterize direct protein interactions with enrichable, cleavable and latent bioreactive unnatural amino acids
Latent bioreactive unnatural amino acids (Uaas) have been widely used in the development of covalent drugs and identification of protein interactors, such as proteins, DNA, RNA and carbohydrates. However, it is challenging to perform high-throughput identification of Uaa cross-linking products due to the complexities of protein samples and the data analysis processes. Enrichable Uaas can effectively reduce the complexities of protein samples and simplify data analysis, but few cross-linked peptides were identified from mammalian cell samples with these Uaas. Here we develop an enrichable and multiple amino acids reactive Uaa, eFSY, and demonstrate that eFSY is MS cleavable when eFSY-Lys and eFSY-His are the cross-linking products. An identification software, AixUaa is developed to decipher eFSY mass cleavable data. We systematically identify direct interactomes of Thioredoxin 1 (Trx1) and Selenoprotein M (SELM) with eFSY and AixUaa.
- 18 June 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-13
Open AccessCharacterize direct protein interactions with enrichable, cleavable and latent bioreactive unnatural amino acids
Latent bioreactive unnatural amino acids (Uaas) have been widely used in the development of covalent drugs and identification of protein interactors, such as proteins, DNA, RNA and carbohydrates. However, it is challenging to perform high-throughput identification of Uaa cross-linking products due to the complexities of protein samples and the data analysis processes. Enrichable Uaas can effectively reduce the complexities of protein samples and simplify data analysis, but few cross-linked peptides were identified from mammalian cell samples with these Uaas. Here we develop an enrichable and multiple amino acids reactive Uaa, eFSY, and demonstrate that eFSY is MS cleavable when eFSY-Lys and eFSY-His are the cross-linking products. An identification software, AixUaa is developed to decipher eFSY mass cleavable data. We systematically identify direct interactomes of Thioredoxin 1 (Trx1) and Selenoprotein M (SELM) with eFSY and AixUaa.
- 26 March 2024
- Published by Elsevier in Tetrahedron Letters
- Vol. 140
Practical synthesis of epocholeone, a plant growth-promoting steroid with long-lasting activity
- 26 March 2024
- Published by Elsevier in Tetrahedron Letters
- Vol. 140
Practical synthesis of epocholeone, a plant growth-promoting steroid with long-lasting activity
- Open Access
- 24 February 2023
- Published by Elsevier in Redox Biology
- Vol. 61, 102642
Mapping protein direct interactome of oxidoreductases with small molecular chemical cross-linkers in live cells
- 24 February 2023
- Published by Elsevier in Redox Biology
- Vol. 61, 102642
Open AccessMapping protein direct interactome of oxidoreductases with small molecular chemical cross-linkers in live cells
- Open Access
- 27 July 2021
- Published by Springer Nature in Cell & Bioscience
- Vol. 11 (1) , 1-14
SNX27-driven membrane localisation of OTULIN antagonises linear ubiquitination and NF-κB signalling activation
Background: Linear ubiquitination is a novel type of ubiquitination that plays important physiological roles in signalling pathways such as tumour necrosis factor (TNF) signalling. However, little is known about the regulatory mechanisms of linear ubiquitination, except the well-described enzymatic regulators E3 ligase linear ubiquitin chain assembly complex (LUBAC) and deubiquitinase OTULIN.Results: Previously, we identified SNX27, a member of the sorting nexin family protein, as a selective linear ubiquitin chain interactor in mass spectrometry-based ubiquitin interaction screening. Here, we demonstrated that the interaction between the linear ubiquitin chain and SNX27 is mediated by the OTULIN. Furthermore, we found that SNX27 inhibits LUBAC-mediated linear ubiquitin chain formation and TNFα-induced signalling activation. Mechanistic studies showed that, upon TNFα stimulation, OTULIN-SNX27 is localised to membrane-associated TNF receptor complex, where OTULIN deubiquitinates the linear polyubiquitin chain that formed by the LUBAC complex. Significantly, chemical inhibition of SNX27-retromer translocation by cholera toxin inhibits OTULIN membrane localization.Conclusions: In conclusion, our study demonstrated that SNX27 inhibits TNFα induced NF-κB signalling activation via facilitating OTULIN to localize to TNF receptor complex.
- 27 July 2021
- Published by Springer Nature in Cell & Bioscience
- Vol. 11 (1) , 1-14
Open AccessSNX27-driven membrane localisation of OTULIN antagonises linear ubiquitination and NF-κB signalling activation
Background: Linear ubiquitination is a novel type of ubiquitination that plays important physiological roles in signalling pathways such as tumour necrosis factor (TNF) signalling. However, little is known about the regulatory mechanisms of linear ubiquitination, except the well-described enzymatic regulators E3 ligase linear ubiquitin chain assembly complex (LUBAC) and deubiquitinase OTULIN.Results: Previously, we identified SNX27, a member of the sorting nexin family protein, as a selective linear ubiquitin chain interactor in mass spectrometry-based ubiquitin interaction screening. Here, we demonstrated that the interaction between the linear ubiquitin chain and SNX27 is mediated by the OTULIN. Furthermore, we found that SNX27 inhibits LUBAC-mediated linear ubiquitin chain formation and TNFα-induced signalling activation. Mechanistic studies showed that, upon TNFα stimulation, OTULIN-SNX27 is localised to membrane-associated TNF receptor complex, where OTULIN deubiquitinates the linear polyubiquitin chain that formed by the LUBAC complex. Significantly, chemical inhibition of SNX27-retromer translocation by cholera toxin inhibits OTULIN membrane localization.Conclusions: In conclusion, our study demonstrated that SNX27 inhibits TNFα induced NF-κB signalling activation via facilitating OTULIN to localize to TNF receptor complex.
- 1 March 2021
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 545, 189-194
The natural compound rutaecarpine promotes white adipocyte browning through activation of the AMPK-PRDM16 axis
- 1 March 2021
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 545, 189-194
The natural compound rutaecarpine promotes white adipocyte browning through activation of the AMPK-PRDM16 axis
- Open Access
- 21 December 2017
- Published by Springer Nature in Nature Communications
- Vol. 8 (1) , 1-10
Spontaneous and specific chemical cross-linking in live cells to capture and identify protein interactions
Covalently locking interacting proteins in situ is an attractive strategy for addressing the challenge of identifying weak and transient protein interactions, yet it is demanding to execute chemical reactions in live systems in a biocompatible, specific, and autonomous manner. Harnessing proximity-enabled reactivity of an unnatural amino acid incorporated in the bait toward a target residue of unknown proteins, here we genetically encode chemical cross-linkers (GECX) to cross-link interacting proteins spontaneously and selectively in live cells. Obviating an external trigger for reactivity and affording residue specificity, GECX enables the capture of low-affinity protein binding (affibody with Z protein), elusive enzyme-substrate interaction (ubiquitin-conjugating enzyme UBE2D3 with substrate PCNA), and endogenous proteins interacting with thioredoxin in E. coli cells, allowing for mass spectrometric identification of interacting proteins and crosslinking sites. This live cell chemistry-based approach should be valuable for investigating currently intangible protein interactions in vivo for better understanding of biology in physiological settings.
- 21 December 2017
- Published by Springer Nature in Nature Communications
- Vol. 8 (1) , 1-10
Open AccessSpontaneous and specific chemical cross-linking in live cells to capture and identify protein interactions
Covalently locking interacting proteins in situ is an attractive strategy for addressing the challenge of identifying weak and transient protein interactions, yet it is demanding to execute chemical reactions in live systems in a biocompatible, specific, and autonomous manner. Harnessing proximity-enabled reactivity of an unnatural amino acid incorporated in the bait toward a target residue of unknown proteins, here we genetically encode chemical cross-linkers (GECX) to cross-link interacting proteins spontaneously and selectively in live cells. Obviating an external trigger for reactivity and affording residue specificity, GECX enables the capture of low-affinity protein binding (affibody with Z protein), elusive enzyme-substrate interaction (ubiquitin-conjugating enzyme UBE2D3 with substrate PCNA), and endogenous proteins interacting with thioredoxin in E. coli cells, allowing for mass spectrometric identification of interacting proteins and crosslinking sites. This live cell chemistry-based approach should be valuable for investigating currently intangible protein interactions in vivo for better understanding of biology in physiological settings.